Ultralife (ULBI) Cash & Equivalents (2010 - 2026)

Ultralife's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $8.9 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 1.96% year-over-year to $8.9 million in Q1 2026; TTM through Mar 2026 was $8.9 million, a 1.96% increase from a year earlier, with the FY2025 full-year figure at $9.3 million, up 36.34% from the prior year.
• Cash & Equivalents slipped to $8.9 million in Q1 2026 per ULBI's latest filing, from $9.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $10.9 million in Q2 2025 and bottomed at $5.1 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $8.3 million (2023), against an average of $7.8 million.
• Across the five-year window, Cash & Equivalents slumped 68.14% in 2022 and soared 84.14% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $5.7 million in 2022, then surged by 79.91% to $10.3 million in 2023, then sank by 33.31% to $6.9 million in 2024, then jumped by 36.34% to $9.3 million in 2025, then retreated by 4.87% to $8.9 million in 2026.
• Per Business Quant, the three latest ULBI Cash & Equivalents figures stand at $8.9 million (Q1 2026), $9.3 million (Q4 2025), and $9.3 million (Q3 2025).